Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. covers the month of April 2020, with a report date of April 2, 2020. The Company, a foreign private issuer based in Israel, reported the completion of a strategic acquisition and a material amendment to its credit facilities.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, or total debt levels. The primary financial disclosure relates to a covenant amendment regarding liquidity requirements.
- Liquidity Covenant: The Company amended its Credit Agreement to increase the specified level of cash liquidity it must maintain.
- Debt Facility: The Credit Agreement involves HCR Collateral Management, LLC as the administrative agent.
Material Changes
Two significant events occurred on March 31, 2020:
- Acquisition of Movantik: Through its subsidiary RedHill Biopharma Inc., the Company completed the acquisition of global rights to Movantik (excluding Europe, Canada, and Israel) from AstraZeneca AB.
- Credit Agreement Amendment: The Company entered into an amendment to its February 23, 2020 Credit Agreement. This amendment specifically increased the required cash liquidity threshold while negotiations for other potential changes to the agreement were ongoing.
Outlook, Risks, and Management Commentary
Management indicated that the liquidity covenant increase was a temporary measure to facilitate ongoing negotiations with HCR Collateral Management, LLC regarding other potential changes to the Credit Agreement. Except for the liquidity covenant adjustment, the terms of the Credit Agreement remain unchanged. The filing incorporates a press release detailing the Movantik acquisition.
Investor Verification Checklist
- Verify the specific dollar amount of the increased cash liquidity requirement in the attached First Amendment to Credit Agreement (Exhibit 1).
- Review the press release (Exhibit 99.1) for details on the purchase price and commercial terms of the Movantik acquisition.
- Monitor future filings for the outcome of the ongoing negotiations with HCR regarding additional changes to the Credit Agreement.
- Confirm the impact of the Movantik acquisition on the Company's future revenue streams and regulatory status in the acquired territories.